CARESIDE INC Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 20 Posts
1 2
Week In Review: Alphamab Oncology Plans $350 Million Hong Kong IPO
Article By: ChinaBio® Today Saturday, December 7, 2019 5:15 PM EDT
Alphamab Oncology, a company developing eight bispecifics for oncology, plans to stage an IPO before the end of the year on the Hong Kong Exchange that could raise up to $350 million.
In this article: AZN, JNJ, MRK, CASI, ASLN
Read
Week In Review: Chi-Med Plans $500 Million Hong Kong IPO
Article By: ChinaBio® Today Saturday, April 20, 2019 4:48 PM EDT
Hutchison China MediTech filed to IPO on the Hong Kong Exchange, following listings in London and on NASDAQ, where it has a market capitalization of over $4 billion. The IPO is expected to raise between $300 million and $500 million.
In this article: RNN, CASI, HCM
Read
Week In Review: Inventis Closes $70 Million Financing To Develop 30 Novel Therapeutics
Article By: ChinaBio® Today Saturday, March 16, 2019 4:22 PM EDT
InventisBio of Shanghai closed a $70 million Series C financing led by Advantech Capital and CMBI, followed by Pudong Innotek. Founded in 2013, InventisBio focuses on discovering and developing novel therapeutics for cancer and metabolic diseases.
In this article: CASI, NTRA
Read
Week In Review: Grifols Pays $1.9 Billion For 26% Stake In Shanghai RAAS
Article By: ChinaBio® Today Saturday, March 9, 2019 4:13 PM EDT
Grifols, a Barcelona maker of plasma-based medicines, acquired a 26% stake in Chinese blood plasma company Shanghai RAASfor $1.9 billion in a non-cash deal. Grifols will exchange a 45% ownership in Grifols Diagnostic Solutions for the RAAS stake.
In this article: CASI, BGNE, GRFS, NVO
Read
Week In Review: China Pharmas Announce Deals Worth $1.5 Billion
Article By: ChinaBio® Today Saturday, December 8, 2018 4:21 PM EDT
WuXi AppTec, China's largest CRO/CMO, completed a $1 billion IPO on the Hong Kong markets, pricing the offering in the middle of the expected range (see story). In May, WuXi became a public company by completing a $328 million IPO in Shanghai.
In this article: RVNC, VBIV, CASI, SPPI
Read
Week In Review: Alphamab Closes $100 Million Series A For Oncology Candidates
Article By: ChinaBio® Today Saturday, November 24, 2018 4:09 PM EDT
Alphamab Oncology, a clinical-stage Suzhou biopharma, completed a Series A funding with over $100 million in capital. Earlier this year, Alphamab Oncology was spun out of Suzhou Alphamab with seven oncology assets and related technology platforms.
In this article: LLY, CASI, BIIB, GILD
Read
Week In Review: Innovent Completes $421 Million Hong Kong IPO; Will Start Trading Next Week
Article By: ChinaBio® Today Saturday, October 27, 2018 5:08 PM EDT
Innovent Biologics has priced its Hong Kong IPO to raise $421 million. The successful IPO shows investors are still interested in young China biopharmas. he IPO values Innovent at $2 billion; its shares will begin trading on October 31.
In this article: CASI, ZLAB
Read
Week In Review: WuXi AppTec To Follow Shanghai IPO With $1 Billion+ Hong Kong IPO
Article By: ChinaBio® Today Saturday, September 22, 2018 4:47 PM EDT
WuXi AppTec has filed for a Hong Kong IPO that is expected to raise at least $1 billion. The company, China's largest CRO/CMO, completed a $354 million IPO on the Shanghai Exchange just over four months ago.
In this article: CASI
Read
Week In Review: CITIC Offers $3.6 Billion To Acquire China Biologic
Article By: ChinaBio® Today Saturday, June 23, 2018 5:27 PM EDT
CITIC Capital has submitted a $3.6 billion bid to acquire China Biologic Products, one of China's top five plasma-based biopharmas (. The bid, which came at a 34% premium to the previous close, was unsolicited and non-binding.
In this article: AZN, CBPO, PCRX, CSLLY, CASI
Read
Week In Review: James Watson To Lead New Shenzhen Biopharma Research Center
Article By: ChinaBio® Today Saturday, March 24, 2018 5:53 PM EDT
James Watson, who co-discovered the double-helix structure of DNA in 1953, will lead a new international life science research center in the International Bio Valley, located in Shenzhen's Dapeng New Area.
In this article: ROG, AVH, NVS, CASI, CBMG, DOVA
Read
Week In Review: C-Bridge Raising Another $650 Million For China Healthcare
Article By: ChinaBio® Today Saturday, February 3, 2018 4:43 PM EDT
Shanghai's C-Bridge Capital is raising capital for its third healthcare private equity fund with a target of $650 million (see story). Just six months ago, C-Bridge closed its second PE fund at a hard cap of $400 million.
In this article: CASI, SRNE, PBYI
Read
Week In Review: Shanghai Pharma Bids In Cardinal China's $1.5 Billion Auction
Article By: ChinaBio® Today Saturday, October 14, 2017 5:29 PM EDT
Shanghai Pharma (SHA: 601607) and FountainVest Partners, a China private equity fund, have submitted second-round bids for Cardinal China's (NYSE: CAH​) drug distribution operations.
In this article: CAH, CASI, CBPO, BIIB
Read
Week In Review: China Leads Global Pharma Innovation, Says Thomson Reuters
Article By: ChinaBio® Today Saturday, May 14, 2016 5:03 PM EDT
According to a recently released Thomson Reuters report, China is the global leader of pharmaceutical innovation. The country is successful because it has fostered a healthy mix of partnerships, pharma industry innovation and scientific research.
In this article: LCI, CASI, HCM, SCLN Also: BABA
Read
Week In Review: BeiGene Schedules $128 Million IPO For February
Article By: ChinaBio® Today Saturday, January 23, 2016 8:07 PM EDT
News briefs for BeiGene, China's Cocoon Networks, China's iCarbonX, CASI Pharma, Shanghai's WuXI Healthcare Ventures, Hungarian pharma company Gedeon Richter, and Perennial Real Estate Holdings of Singapore.
In this article: CASI, NURO
Read
Premarket Biotech Digest | Sector News Brief
Article By: KKD Healthcare Analytics Thursday, January 21, 2016 3:12 AM EDT
The sector news section of our extended daily premarket digest publication.
In this article: JNJ, TBIO, CASI, AKRX, OSIR, XON, MBVX, GLPG, SMMT
Read
E CASI Pharmaceuticals Receives Orphan Drug Designation For Liver Cancer Drug
Article By: Terry Chrisomalis Wednesday, October 14, 2015 4:58 PM EDT
Shares of CASI Pharmaceuticals, Inc. ended the day up 40%, after the company announced that it had received Orphan Drug Designation from the European Union.
In this article: CASI
Read
1 to 16 of 20 Posts
1 2